Harvard Medical School is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Harvard Medical School (HMS) is one of the world's leading institutions for neurodegenerative disease research, with extensive programs in Alzheimer's disease, Parkinson's disease, ALS, and other disorders. The school encompasses 18 affiliated hospitals and research centers in the Boston area.
| Lab/Center | Focus | Key Faculty |
|---|---|---|
| Tanzi Lab | Amyloid and Alzheimer's | Rudolph Tanzi |
| Hyman Lab | Neuroinflammation | Steven Hyman |
| Selkoe Lab | APP processing | Dennis Selkoe |
| Holtzman Lab | Tau and biomarkers | David Holtzman |
| Johnson Lab | Clinical trials | Keith Johnson |
| Sperling Lab | Preclinical AD | Reisa Sperling |
Harvard Medical School offers extensive training in neurodegenerative disease research through:
The institution maintains active research programs in neurodegenerative disease research across multiple departments and centers.
The study of Harvard Medical School has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.